AlzeCure to partake in Redeye Theme: Alzheimer on March 21

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drug candidates for CNS diseases, focusing on Alzheimer's disease and pain, announced today that the company's CEO Martin Jönsson will participate in Redeye’s event focused on Alzheimer’s disease between 2 p.m. and 3 p.m. CET on March 21, 2024.

AlzeCure, along with Bioarctic and Alizinova, have been invited to a panel discussion to talk about the science behind their drug candidates, the remaining need and what it takes to successfully launch a new generation of Alzheimer's drugs.

Each company opens with a one-minute presentation and then participates in a 10-minute Q&A led by Redeye's analyst. Martin Jönsson begins his presentation at 14.20. The event, which is in Swedish, ends with a panel discussion in which all companies participate.

The live broadcast is available via the following link: https://www.redeye.se/events/975970/redeye-theme-alzheimer-2